GenMark Diagnostics, Inc.
Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | $169.1M | $86.8M | $69.9M | $52.3M | $49.3M | $39.4M |
| Operating income | −$5.0M | −$10.9M | −$10.8M | −$59.5M | −$49.0M | −$41.5M |
| Net income | −$7.0M | −$12.1M | −$11.4M | −$61.9M | −$50.6M | −$42.2M |
| Total assets | $223.5M | $111.5M | $93.0M | $122.3M | $80.3M | $70.7M |
| Total liabilities | $129.3M | $99.3M | $59.4M | $51.1M | $42.2M | $22.1M |
| Equity | $94.2M | $12.2M | $33.5M | $71.2M | $38.2M | $48.6M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 60.8M | 55.2M | 55.2M | 47.1M | 42.8M | 41.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −3.0%
- Net margin
- −4.1%
- Return on equity
- −7.4%
- Return on assets
- −3.1%
- Return on capital (ROCE)
- −2.8%
- Liabilities / assets
- 57.9%
- Debt / equity
- 1.37×
- Book value / share
- $1.55
- Revenue growth (YoY)
- 94.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- -3.38distress
- Accruals / assets
- −5.9%clean
- Beneish M-Score
- -2.18normal
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 2 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Giles Lisa M.Director | Apr 22, 2021 | U | 81,572 | $24.05 |
| Kagnoff MichaelDirector | Apr 22, 2021 | U | 137,319 | $24.05 |
| Fox JamesDirector | Apr 22, 2021 | U | 182,017 | $24.05 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventApr 22, 2021
- Entered a material agreementMar 15, 2021
- Regulation FD disclosureMar 15, 2021
- Results of operationsFeb 25, 2021
- Director / officer changeFeb 24, 2021
- Results of operationsJan 11, 2021
- Results of operationsOct 28, 2020
- Results of operationsOct 8, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ACONSONANCE CAPITAL MANAGEMENT LPFeb 14, 2022
- SC 13G/AMay 10, 2021
- 15-12BMay 3, 2021
- EFFECTApr 27, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
- S-8 POSApr 22, 2021
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.